- ►diabetesjournals.org F Pistrosch, J Passauer, S Fischer, K Fuecker … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—Glycemic control was comparable under rosiglitazone and nateglinide.
Rosiglitazone ameliorated insulin resistance by 60% compared with nateglinide.
ACh response was significantly increased after rosiglitazone treatment ... Cited by 175 - Related articles - BL Direct - All 5 versions
- Free from Publisher A Natali, S Baldeweg, E Toschi, B Capaldo, D … - Diabetes Care, 2004 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In a randomized, double-blind design, we assigned
74 type 2 diabetic patients to rosiglitazone (8 mg/day), metformin (1,500
mg/day), or placebo treatment for 16 weeks and measured insulin sensitivity ... Cited by 129 - Related articles - BL Direct - All 5 versions
TD Wang, WJ Chen, JW Lin, MF Chen, YT … - The American journal of cardiology, 2004 - Elsevier Fifty nondiabetic patients who met a modified National Cholesterol Education
Program definition for the metabolic syndrome were randomized to receive either
rosiglitazone (4 mg/day; N = 25) or placebo (n = 25) for 8 weeks. Compared ... Cited by 151 - Related articles - All 10 versions
- ►cardiologyfellowship.org [PDF] JS Sidhu, D Cowan, JC Kaski - The American journal of cardiology, 2004 - Elsevier Recent data have shown that peroxisome proliferator-activated receptor-γ
agonists may exert protective effects on the vascular endothelium by
amelioration of insulin resistance and through direct anti-inflammatory ... Cited by 76 - Related articles - All 10 versions
AI Vinik, KB Stansberry, PM Barlow - Journal of Diabetes and its Complications, 2003 - Elsevier Type 2 diabetes mellitus (T2DM) is associated with an increased risk of micro-
and macrovascular complications, causing considerable morbidity and mortality.
Endothelial dysfunction and insulin resistance have been strongly ... Cited by 32 - Related articles - All 11 versions
- ►ahajournals.org J Hetzel, B Balletshofer, K Rittig, D Walcher … - Arteriosclerosis, thrombosis, and vascular biology, 2005 - Am Heart Assoc Methods and Results— Short-term treatment (21 days) of healthy subjects (n=10)
did not significantly change blood glucose levels or lipid profile. In contrast,
rosiglitazone significantly increased flow-mediated, endothelium-dependent ... Cited by 107 - Related articles - All 10 versions
- ►diabetesjournals.org N Satoh, Y Ogawa, T Usui, T Tagami, S Kono … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A total of 136 Japanese type 2 diabetic patients
were included and divided into two groups: the pioglitazone-treated group (30 mg
daily for 3 months) (n = 70) and the untreated control group (n = 66). The ... Cited by 251 - Related articles - BL Direct - All 5 versions
- ►medicinainternacba.com.ar [PDF] - Free from Publisher H Sourij, R Zweiker, TC Wascher - Diabetes Care, 2006 - Am Diabetes Assoc OBJECTIVE—About one of five patients with coronary artery disease (CAD)
suffers from previously unknown, predominantly postprandial type 2 diabetes. In
the process of atherogenesis and the subsequent increased cardiovascular ... Cited by 38 - Related articles - BL Direct - All 8 versions
F Pistrosch, K Herbrig, U Oelschlaegel, S … - Atherosclerosis, 2005 - Elsevier We investigated 10 recently diagnosed type 2 diabetic patients and 10 age and
sex matched healthy control subjects. After baseline examination of metabolic
parameters and EPC, patients received 4 mg rosiglitazone bid for 12 weeks. ... Cited by 97 - Related articles - All 12 versions
T Horio, M Suzuki, I Takamisawa, K Suzuki, … - American Journal of Hypertension, 2005 - Elsevier Pioglitazone did not decrease fasting plasma glucose and hemoglobin A 1c (HbA 1c
) in the nondiabetic subjects, although the area under the curve for glucose and
insulin on OGTT significantly decreased. A marked decrease in SSPG was ... Cited by 19 - Related articles - All 4 versions
